Mount Sinai Hospital

Tisch Cancer Institute

New York, NY

Sorting 3 by

Accepting patients

R289

Phase 1b Study of R289 in Patients with Lower-risk Myelodysplastic Syndromes (LR MDS)
Learn more
  • IRAK 1 Inhibitor
  • IRAK 4 Inhibitor
  • Phase 1/2

Accepting patients

TCR Engineered Donor T-Cells

A Controlled Multi-Arm Ph1 Study Evaluating the Safety and Feasibility of TCR Engineered Donor TCells Targeting HA1 (TSC-100) or HA2 (TSC-101) in HLA-A0201 Positive Patients Undergoing Haploidentical Allogeneic Stem Cell Transplantation
Learn more
  • T Cell (Allogeneic)
  • Phase 1
  • Has results

Accepting patients

MAXILUS

A Phase 3b, Open-label Study Evaluating the Efficacy and Safety of Luspatercept (BMS-986346/ACE-536) Initiated at Maximum Approved Dose in LR-MDS With IPSS-R Very Low-, Low-, or Intermediate-risk Who Require RBC Transfusions (MAXILUS)
Learn more
  • Erythroid Maturation Agent (EMA)
  • Red Blood Cell Stimulant
  • Phase 3